Last reviewed · How we verify

olmesartan/amlodipine + hydrochlorothiazide, if necessary.

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · FDA-approved active Small molecule

olmesartan/amlodipine + hydrochlorothiazide, if necessary. is a Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Small molecule drug developed by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. It is currently FDA-approved for Hypertension (essential hypertension in patients not adequately controlled on dual therapy).

This combination blocks angiotensin II receptors, inhibits calcium channels, and reduces sodium reabsorption in the kidney to lower blood pressure through multiple complementary pathways.

Olmesartan/amlodipine/hydrochlorothiazide is a triple-combination antihypertensive marketed by Daiichi Sankyo Europe under the brand Sevikar HCT, combining an angiotensin II receptor blocker (ARB), calcium channel blocker (CCB), and thiazide diuretic. The fixed-dose combination targets hypertension through three complementary mechanisms: ARB-mediated vasodilation and aldosterone suppression, CCB-induced vascular smooth muscle relaxation, and thiazide-induced sodium/fluid reduction, enabling synergistic blood pressure reduction in resistant or difficult-to-control hypertension. Approved across Europe and multiple international markets, Sevikar HCT represents a mature, well-established therapy for patients requiring intensified antihypertensive coverage. Clinical differentiation centers on superior central aortic pressure reduction versus dual-agent comparators and convenience of single-pill therapy. Commercial significance is moderate within the crowded antihypertensive market; peak sales remain below $500M globally. Pipeline development has focused on formulation optimization and comparative efficacy studies rather than new indications.

At a glance

Generic nameolmesartan/amlodipine + hydrochlorothiazide, if necessary.
SponsorDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Drug classAntihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)
TargetAngiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter (NCC)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Olmesartan is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and aldosterone release. Amlodipine is a calcium channel blocker that relaxes vascular smooth muscle. Hydrochlorothiazide is a thiazide diuretic that reduces blood volume by increasing sodium and water excretion. Together, these three agents provide synergistic antihypertensive effects.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about olmesartan/amlodipine + hydrochlorothiazide, if necessary.

What is olmesartan/amlodipine + hydrochlorothiazide, if necessary.?

olmesartan/amlodipine + hydrochlorothiazide, if necessary. is a Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) drug developed by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, indicated for Hypertension (essential hypertension in patients not adequately controlled on dual therapy).

How does olmesartan/amlodipine + hydrochlorothiazide, if necessary. work?

This combination blocks angiotensin II receptors, inhibits calcium channels, and reduces sodium reabsorption in the kidney to lower blood pressure through multiple complementary pathways.

What is olmesartan/amlodipine + hydrochlorothiazide, if necessary. used for?

olmesartan/amlodipine + hydrochlorothiazide, if necessary. is indicated for Hypertension (essential hypertension in patients not adequately controlled on dual therapy).

Who makes olmesartan/amlodipine + hydrochlorothiazide, if necessary.?

olmesartan/amlodipine + hydrochlorothiazide, if necessary. is developed and marketed by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (see full Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company pipeline at /company/daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company).

What drug class is olmesartan/amlodipine + hydrochlorothiazide, if necessary. in?

olmesartan/amlodipine + hydrochlorothiazide, if necessary. belongs to the Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) class. See all Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) drugs at /class/antihypertensive-combination-arb-calcium-channel-blocker-thiazide-diuretic.

What development phase is olmesartan/amlodipine + hydrochlorothiazide, if necessary. in?

olmesartan/amlodipine + hydrochlorothiazide, if necessary. is FDA-approved (marketed).

What are the side effects of olmesartan/amlodipine + hydrochlorothiazide, if necessary.?

Common side effects of olmesartan/amlodipine + hydrochlorothiazide, if necessary. include Dizziness, Headache, Fatigue, Hyperkalemia (with ARB component), Hypokalemia (with thiazide component), Hyperuricemia.

What does olmesartan/amlodipine + hydrochlorothiazide, if necessary. target?

olmesartan/amlodipine + hydrochlorothiazide, if necessary. targets Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter (NCC) and is a Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic).

Related